Summary of Key Highlights
In the first half of 2026, China's innovative pharmaceutical industry witnessed comprehensive breakthroughs: the number of domestically developed novel drugs (with new targets and mechanisms) surpassed that of the entire previous year, the total value of foreign licensing transactions approached the annual figure from the previous year, and the marketization speed of these new drugs accelerated significantly. At the same time, healthcare policies continued to be optimized to support genuine innovation, marking China's transition from a major pharmaceutical producer to a leader in innovative drug research and development.
Detailed Analysis
1. Surge in Domestic "First-In-Class Drugs": More Discovered in Half a Year Than in the Entire Previous Year
"Novel targets and mechanisms" refer to treatment approaches that have not been attempted before—either targeting completely new disease targets (such as a specific protein on cancer cells) or using entirely new methods of treating diseases (for example, enabling the immune system to precisely attack tumors). These drugs are considered the "hard currency" within the realm of innovative pharmaceuticals.
In 2025, only 4 out of the 11 novel drugs approved in China were domestically developed; however, in the first half of 2026, the number of domestically developed first-in-class drugs reached 11, exceeding the total for the entire previous year. Among these, several are world-firsts:
- The world's first bispecific antibody ADC drug (similar to a "biological missile" that can precisely target and kill cancer cells);
- The world's first CAR-T cell therapy for treating solid tumors (previously limited to blood cancers but now also applicable to lung and stomach cancers);
- The world's first monoclonal antibody for treating hepatitis B and D (bringing new hope to patients with chronic liver diseases);
- China's first domestically developed radiotherapy drug that uses radioactive substances to target tumors precisely.
This indicates that China has moved from following international trends in innovative pharmaceuticals to leading the global development.
2. Innovative Drugs Generating Significant Revenue Abroad: Transactions in Half a Year Nearly Match the Annual Total, with Rising International Recognition
"Foreign licensing" involves selling the overseas rights (such as sales and further development) of Chinese-developed drugs to foreign companies in exchange for cash or future profit-sharing. This reflects the international market's recognition of the value of these Chinese innovations.
In 2025, the total value of foreign licenses for Chinese innovative drugs was $135.655 billion; in the first half of 2026, it approached $110 billion, which is nearly 80% of the annual figure from the previous year. This suggests that foreign pharmaceutical companies are willing to invest heavily in Chinese technologies, indicating a period of rapid growth for Chinese innovative drugs on the global market.
3. New Drugs Quickly Available Nationwide: Faster Distribution and Access through Healthcare Insurance
In the past, it could take several months or even half a year for new drugs to be available in hospitals. However, this process has significantly accelerated. For example, the world's first bispecific antibody ADC drug developed by Chengdu Bio-TheraTech was approved for market release on June 22nd and was distributed to nearly 700 hospitals and pharmacies in over 200 cities across the country within less than a week (on July 8th), making it readily available to patients. More importantly, this drug has been included in this year's healthcare insurance negotiation list—negotiations between pharmaceutical companies and health authorities determine the price, and once included in the insurance, patients can afford the medication. This year, 343 new drugs were approved within five years, indicating that pharmaceutical companies are eager to get their products covered by healthcare insurance, significantly improving marketization efficiency.
4. Healthcare Policies Supporting Innovation: A Win-Win for Both Patients and Companies
The health authorities have clearly stated that they will optimize the healthcare system to support genuine innovation:
- Evaluating drug effectiveness using "real-world data" (i.e., actual clinical outcomes rather than just laboratory results);
- Expanding multiple payment options (e.g., combining commercial insurance and government funding);
- Aligning evaluation standards with international practices.
The core of these policies is to support genuine innovation—drugs that truly address patients' needs, not merely superficial improvements or dosage adjustments. This environment encourages pharmaceutical companies to invest in research and development, ensuring that patients have access to affordable and effective treatments, creating a positive cycle.
Conclusion
The achievements in the first half of 2026 represent more than just numerical milestones; they signify a qualitative shift in China's pharmaceutical industry from being a follower to a leader in innovation. From the emergence of world-first drugs to a surge in international licensing, and with supportive healthcare policies, Chinese innovative drugs are becoming a significant force in the global pharmaceutical market.